HAS Healthcare Advanced Synthesis Group Announces Strategic Investments in Biodelphis Therapeutics
Share this article
HAS Healthcare Advanced Synthesis (Ticino) and Biodelphis Therapeutics (Vaud) announced the signing of a strategic agreement to support the development and GMP manufacturing of Antibody Protease Inhibitor Conjugates, an emerging class of targeted therapeutics designed to selectively inhibit disease‑driving proteases.
This collaboration combines HAS Group long‑standing expertise in complex bioconjugation, process development, and clinical‑grade manufacturing with Biodelphis Therapeutics’ pioneering APIC platform, a novel drug modality engineered to deliver highly selective protease inhibition directly to diseased tissues.
Under the agreement, the two companies will work closely to accelerate the transition of first‑in‑class APIC candidates from early development into robust, scalable manufacturing processes. The partnership aims to strengthen the path toward clinical evaluation by integrating Biodelphis’ innovative therapeutic design with HAS/Cerbios’ proven capabilities in high‑quality bioconjugate production.
About HAS Healthcare Advanced Synthesis Group
HAS Healthcare Advanced Synthesis is part of the HAS Group in Ticino, an integrated CDMO platform established in 2025 through the acquisition of Cerbios‑Pharma SA. The Group has complementary capabilities in chemical and biological development, specializing in APIs, HPAPIs, anticancer compounds, linker‑payloads, and ADCs.
About Biodelphis Therapeutics
Biodelphis Therapeutics is a Swiss biotech startup, based in Lausanne that develops next‑generation protease‑targeting medicines using its proprietary Antibody‑Peptide Inhibitor Conjugate (APIC) technology. Spun out of EPFL, the company focuses on creating highly selective, cell‑targeted protease inhibitors designed to overcome the toxicity and specificity limitations of traditional small‑molecule approaches. Its APICore platform enables rapid design and optimization of potent peptide inhibitors that are activated only within intended cells, such as tumor cells, improving both efficacy and safety. Biodelphis is advancing a preclinical pipeline of first‑in‑class candidates targeting cathepsin proteases for oncology, bone health, and autoimmune diseases, with lead programs in lung adenocarcinoma and osteoporosis.
➡️ Source: Press Release | 📸 Aaron Simone Petruzzella, Founder of Biodelphis Therapeutics, and Riccardo Braglia, Chairman of HAS Healthcare Advanced Synthesis, both at Swiss Biotech Day 2026. ©Biodelphis Therapeutics